Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.68 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.68 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 5/20 | 0.67 |
| ▸ | CA1 | P00915 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 5/20 | 0.67 |
| ▸ | CA7 | P43166 | 5/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.67 |
| ▸ | ALPL | P05186 | 2/20 | 0.67 |
| ▸ | ALPG | P10696 | 2/20 | 0.67 |
| ▸ | ALPI | P09923 | 1/20 | 0.67 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.67 |
| ▸ | MGAM | O43451 | 1/20 | 0.65 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | SI | P14410 | 1/20 | 0.65 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202723 | 0.85 | RAB9A (0.70) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL18825270 | 0.84 | CA12 (0.71) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL25516473 | 0.80 | CDYL2 (0.63) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL22381005 | 0.80 | CA12 (1.00) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL6201409 | 0.77 | CA12 (0.68) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL1035783 | 0.74 | EGLN3 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28326060 | 0.73 | CYP11B1 (0.69) | SMN1; SMN2ALDH1A1IDO1LMNA | |
| SCHEMBL20672328 | 0.73 | F10 (0.68) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL4284703 | 0.73 | KDM4E (0.61) | CDYL2CDYLCDY1; CDY1BCA12CA1 | |
| SCHEMBL10247491 | 0.73 | KDM4E (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1869023-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | Vicore Pharma AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006109048-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | CDYL2 2577/4885CDYL 2344/4885CDY1; CDY1B 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.